Clinical trials: Rhinitis Seasonal
Seasonal Allergic Rhinitis
Compare Captisol-Enabled (CE) Budesonide + Azelastine Nasal Solution and Rhinocort Aqua + Astelin in an Environmental Exposure Chamber (EEC) Study of Allergic Rhinitis
The primary objective of this study was to compare Placebo to Captisol-Enabled Budesonide + Azelastine in a single spray and two separate sprays (Budesonide + Azelastine) in patients with Seasonal Allergic Rhinitis exposed to…
- Trial name
- NCT00940953
- Testing
- Budesonide + Azelastine
- Where
- Canada
- Volunteers
- 108 people
- Sponsor
- Ligand Pharmaceuticals
Rhinitis, Allergic, Perennial and Seasonal
Pharmacokinetic Study of Levocetirizine Oral Solution
This study will be a single center, open-label, randomized, single dose, in the fasted condition and 2-way crossover study to evaluate the pharmacokinetics, the safety and tolerability of levocetirizine oral solution 5 mg and…
- Trial name
- NCT01622283
- Testing
- Levocetirizine, Cetirizine
- Where
- Japan
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Seasonal Allergic Rhinitis, Seasonal Allergic Conjunctivitis
Safety and Efficacy of Ectoin Allergy Nasal Spray and Ectoin Allergy Eye Drops in the Treatment of Seasonal Allergic Rhinitis (SAR) in Children and Adolescents
Ectoin acts on membranes by forming an Ectoin-Hydro-Complex therewith providing a protection against external agents like aeroallergens.
- Trial name
- NCT01342601
- Testing
- ect4allergy Nasal Spray (ANS01) and Eye Drops (AAT01)
- Where
- 8 sites in Germany
- Volunteers
- 72 people
- Sponsor
- Bitop AG
Rhinitis, Allergic, Seasonal, Rhinitis, Allergic, Perennial
Observation of Side Effects and Effectiveness of Desloratadine (Aerius) Syrup in Filipino Children (Study P05634)
The purpose of this study is to observe the side effects of desloratadine syrup and how effective it is in relieving symptoms of allergic rhinitis or hives in Filipino children.
- Conditions
- Rhinitis, Allergic, Seasonal, Rhinitis, Allergic, Perennial, Urticaria
- Trial name
- NCT00761527
- Testing
- Desloratadine Syrup
- Volunteers
- 2,980 people
- Sponsor
- Organon and Co
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Study With High Dose PURETHAL Mites in Allergic Rhinitis/Rhinoconjunctivitis Patients
The aim of the study is to establish the maximum tolerated dose of PURETHAL Mites that is achieved by 90% of the patients with less than 20% of the injections giving rise to a swelling of > 5 cm and the optimal regimen to reach…
- Trial name
- NCT00973453
- Testing
- PURETHAL Mites 20,000 AUeq/ml
- Where
- 6 sites in Germany
- Volunteers
- 48 people
- Sponsor
- HAL Allergy
Allergic Rhinitis, Healthy Volunteer
DSP-3025 Study of Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of Season
Investigate safety/tolerability after a single dose intranasal administration of DSP-3025 comparator placebo to healthy male volunteers and seasonal allergic rhinitis male patients out of season.
- Trial name
- NCT00925678
- Testing
- DSP-3025
- Where
- Japan
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Sumitomo Pharma Co., Ltd.
Seasonal Allergic Rhinitis
Efficacy and Safety of SPARC1310 in Seasonal Allergic Rhinitis
The study will assess the efficacy and safety of SPARC1310 when compared to placebo and active control
- Trial name
- NCT01940146
- Testing
- SPARC1310 I, SPARC1310 II, SPARC1310 III
- Where
- Canada
- Volunteers
- 222 people
- Sponsor
- Sun Pharma Advanced Research Company Limited
Rhinitis, Allergic, Seasonal
Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006)
The purpose of this study is to assess the safety and tolerability of MK-3641 (short ragweed [Ambrosia artemisiifolia] extract, SCH 039641, RAGWITEK®) sublingual tablets and MK-7243 (Timothy grass [Phleum pratense] extract, SCH…
- Trial name
- NCT02256553
- Testing
- MK-3641 12 Amb a 1-U (short ragweed extract), MK-7243 2800 BAU (Timothy grass extract), Rescue Medication
- Volunteers
- 102 people
- Sponsor
- ALK-Abelló A/S
Hayfever, Allergy Pollen
Breathe-Easy: Hayfever Care for Patients With Seasonal Allergic Rhinitis
This waitlist-controlled trial aims to evaluate the therapeutic effectiveness of Hayfever Care by assessing disease-specific symptoms over a 4-week period.
- Conditions
- Hayfever, Allergy Pollen, Allergic Rhinitis
- Trial name
- NCT06765239
- Testing
- Hayfever Care, Wait-list Control
- Where
- India
- Volunteers
- 63 people
- Sponsor
- Innowage Limited
Allergic Rhinitis, Allergic Conjunctivitis
Demonstration of Equivalence and Early Onset of a Novel Anti-allergic Nasal Spray Compared to Marketed Nasal Spray
Intranasal corticosteroids are accepted as safe and effective first-line therapy for allergic rhinitis, especially in treatment of persistent symptoms.
- Conditions
- Allergic Rhinitis, Allergic Conjunctivitis, Hayfever
- Trial name
- NCT03755557
- Testing
- Rhinocort, Budesolv
- Where
- Austria
- Volunteers
- 82 people
- Sponsor
- Marinomed Biotech AG
Seasonal Allergic Rhinitis, Asthma
Study of Grass-SPIRE in Subjects With Grass Allergies and Asthma
The purpose of this study is to determine whether it is safe to administer Grass-SPIRE to subjects suffering from both grass allergy and asthma
- Trial name
- NCT02161107
- Testing
- Grass-SPIRE
- Where
- 5 sites in Canada
- Volunteers
- 54 people
- Sponsor
- Circassia Limited
Seasonal Allergic Rhinitis
Dymista Allergen Chamber - Onset of Action Study
This study is to assess the onset of action of fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray (Dymista) in treating the nasal symptoms of seasonal allergic rhinitis (SAR) induced by an…
- Trial name
- NCT04652245
- Testing
- Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 3, Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 5
- Where
- Canada
- Volunteers
- 216 people
- Sponsor
- MEDA Pharma GmbH & Co. KG
Rhinitis, Allergic, Seasonal, Conjunctivitis, Allergic
Immunotherapy With Depigmented and Polymerized Allergen Extract of Phleum Pratense
The objective of this trial is to evaluate the clinical effectiveness of the administration of a depigmented and polymerized allergen extract of Phleum pratense in the rhinoconjunctivitis and/or asthma of slight or moderate…
- Conditions
- Rhinitis, Allergic, Seasonal, Conjunctivitis, Allergic, Asthma
- Trial name
- NCT00501527
- Testing
- Immunotherapy with modified extract of P. pratense pollen
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Laboratorios Leti, S.L.
Rhinitis, Allergic, Perennial and Seasonal
A Study to Assess Intranasal Repeat Dose Effect of Levocabastine in the Subjects With Allergic Rhinitis
This study will be a randomized, double blind, placebo controlled, 3-way cross over design in allergic rhinitis subjects. Subjects will receive repeat doses of intra-nasal levocabastine for 7 days in each period and the duration…
- Trial name
- NCT01949051
- Testing
- Levocabastine
- Where
- Canada
- Volunteers
- 78 people
- Sponsor
- GlaxoSmithKline
Seasonal Allergic Rhinitis
A Study to Determine the Capacity of VAK694 When Combined With Allergen Immunotherapy to Bring About Specific Immune Tolerance
The purpose of the study is to determine whether VAK694 when combined with subcutaneous immunotherapy leads to long term immune tolerance to allergen in individuals with seasonal allergic rhinitis.
- Trial name
- NCT01018693
- Testing
- VAK694; Alutard Avanz SQ
- Where
- United Kingdom
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals
Seasonal Allergic Rhinitis
A Placebo-controlled Study of 2-day Pre-treatment With Fexofenadine in Seasonal Allergic Rhinitis
This study is a proof-of-concept study to demonstrate if a daily dose of a 2-days pre-treatment of Fexofenadine 180mg is effective in alleviating the AR symptoms and to assess the additional benefit to the patient in terms of…
- Trial name
- FEXPRESAR (NCT05692154)
- Testing
- Fexofenadine
- Where
- Canada
- Volunteers
- 95 people
- Sponsor
- Opella Healthcare Group SAS, a Sanofi Company
Rhinitis, Allergic, Perennial and Seasonal, Rhinitis, Allergic
A Study to Compare the Efficacy and Safety of Fluticasone Furoate Nasal Sprays (FFNS) 55 Microgram (mcg) and 110 mcg in Chinese Pediatric Subjects With Allergic Rhinitis (AR)
This Phase IV interventional study is a multi-center, randomized, double-blind, placebo-controlled parallel study to evaluate the efficacy and safety of FFNS110 mcg and 55 mcg once daily versus vehicle placebo aqueous nasal spray…
- Trial name
- NCT02424539
- Testing
- FFNS
- Where
- 16 sites in China
- Volunteers
- 358 people
- Sponsor
- GlaxoSmithKline
Seasonal Rhinitis and/or Rhinoconjunctivitis, Birch Pollen Allergy
SUBLIVAC® Birch PROBE Study
Objective of the study is to show, on an exploratory basis, that treatment with SUBLIVAC Birch is also effective compared to treatment with Staloral Birch by means of reduction in allergic symptoms during nasal provocation in…
- Trial name
- NCT00932607
- Testing
- sublingual immunotherapy
- Where
- Germany
- Volunteers
- 74 people
- Sponsor
- HAL Allergy
Rhinitis, Allergic, Seasonal
Single and Repeat Dose First Time in Human Study for an Intranasal H1/H3 Dual Antagonist in Healthy Male Subjects
This is a double-blind, placebo-controlled, randomized single dose escalation study and a double-blind, placebo-controlled, randomised parallel group 14-days once daily repeat dose study to investigate safety, tolerability and…
- Trial name
- NCT00694993
- Testing
- GSK1004723
- Where
- Germany
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Seasonal Allergic Rhinoconjunctivitis
Safety Study of Grass Pollen-derived Peptides to Treat Seasonal Allergic Rhinoconjunctivitis
The purpose of this study is to determine whether the oral administration of grass pollen peptides is safe and effective in the treatment of allergic rhinitis.
- Trial name
- NCT00833066
- Testing
- gpASIT+TM
- Where
- 4 sites in Belgium
- Volunteers
- 54 people
- Sponsor
- BioTech Tools S.A.